China's State Drug Administration approves Gilead compound preparation bitovi® (Biken pronosis) for the treatment of HIV-1 virus infection

Recently, Gilead Sciences (NASDAQ: GILD) announced that its daily service mono-combination formulation, the Pitutovi ® (Biken pronotablets), has been approved by China's NationalMedicines(http://Regulatory Authority for the treatment of HIV-1 infectionAbout TheDrug(http://structure of the Pitutovi ®
the Pitutovi ® combines the innovative excitant-free integrated enzyme chain transfer inhibitor (INSTI) bikitivir, as well as the proven dual nucleoside anti-retroviral inhibitor backbone drug (NRTI) daco-® (Enquitafenolinopinopa, enthofa 200mgPC/propofol25mg/ TAF5mg/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF5/TAF55/TAF5/TAF5,25mg/ TAF5mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mg, 25mgThe ® is the smallest combination of combination slivers available based on integrated enzyme chain transfer inhibitorsThe ® of the pitovis is suitable in China for adults infected with human immunodeficiency virus type 1 (HIV-1) as a complete treatment, and there is current and no evidence of viral resistance to integrated enzyme inhibitor strains, enpitaphins or monoofonesThe approval of the Pittovi ® is supported by data from four clinical Phase 3 studies currently under way by Gilead: including 1489 and 1490 clinical studies for adults with initial HIV-1 infection, and 1844 and 1878 clinical studies for adults with viralally suppressed treatment of HIV-1 infection2,414 subjects participated in clinicaltrial
seines (http://of the pedith® or control group, and the subjects had diverse population characteristics, including adult patients of different ages and races security
48-week results showed that the pitovy ® treatment group achieved the main virological endpoint indicator of non-poor efficacy No subjects developed therapeutic lymo resistance in the ® treatment group, and no subjects stopped taking the ® due to adverse events in the kidneys, bones, or liver 　　The common adverse reactions of subjects taking the ® of the bitovitowere were diarrhea, nausea and headache.